bioAffinity Technologies

bioAffinity Technologies is a biotechnology company based in the United States, founded in 2014. The company focuses on addressing the critical need to detect and treat cancer at the cellular level, particularly targeting early-stage lung cancer and other lung diseases. Their flagship product, CyPath® Lung, is a noninvasive test exhibiting high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. It has been licensed by Precision Pathology Services for further development and commercial sales as a Laboratory Developed Test.

This innovative product has the potential to significantly improve overall diagnostic accuracy, resulting in increased survival rates, reduced need for invasive procedures, and decreased patient anxiety and medical costs. The company secured a notable $2.50M Post-IPO Equity investment on 06 March 2024, indicating investor confidence in their technology and growth prospects.